Endocyte to Present at the IASLC 17th World Conference on Lung Cancer

WEST LAFAYETTE, Ind., Dec. 01, 2016 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that data from ongoing phase 1 trials of Endocyte’s SMDC EC1456 will be presented at the IASLC 17^th World Conference on Lung Cancer on Wednesday, Dec. 7, at 2:30 P.M. CET. The conference will be held at the Messe Wien Exhibition & Congress Center in Vienna, Austria.

The presentation will be available on Endocyte’s website following presentation at the conference.

Presentation is as follows:

About EC1456 and etarfolatide

EC1456 is an investigational therapeutic SMDC constructed of folic acid conjugated through a spacer and releasable linker system to a potent cytotoxic microtubule inhibitor, TubBH. The high affinity of the folic acid ligand for the FR allows for the active and specific targeting of EC1456 to FR-expressing cancer cells.  The FR is highly expressed in several epithelial cancers (e.g. ovarian, NSCLC) but is expressed at low levels in most normal tissues. 

Etarfolatide is an FR-targeted companion imaging agent being co-developed to characterize whole body FR expression in real time, to identify patients most likely to benefit from EC1456 therapy.  EC1456 and etarfolatide are currently being evaluated in a phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases.  Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies.  The company’s SMDCs actively target receptors that are over-expressed on diseased cells relative to healthy cells.  This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone.  The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.

Contacts:
Michael Schaffzin, Stern Investor Relations, Inc., (212) 362-1200, [email protected]